Search clinical trials for: Gemcitabine Hydrocholoride

Total 2810 results

Peptomyc S.L.

Recruiting

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02)

Metastatic Pancreatic Cancer

Spain
Zhejiang Cancer Hospital

Recruiting

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Advanced Ovarian Cancer | Serous Ovarian Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (RCT-PAAG)

Pancreatic Adenocarcinoma Metastatic

China
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma

United States
Institut Paoli-Calmettes

Not yet recruiting

Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients (GemSign-01)

Cancer Of Pancreas
Nataliya Uboha
Gilead Sciences; University of Wisconsin, Madison; Arcus Biosciences, Inc.

Recruiting

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Carcinoma

United States
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
Gruppo Oncologico del Nord-Ovest

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (PURITY)

Cholangiocarcinoma | Biliary Tract Cancer

Italy
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
State University of New York - Downstate Medical...

Recruiting

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer (C3)

Pancreatic Cancer Metastatic

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Air Force Military Medical University, China

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma

China
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC; G1 Therapeutics, Inc.

Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)

Metastatic Triple-Negative Breast Cancer

United States
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Yonsei University

Not yet recruiting

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (DOVE)

Uterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina Neoplasm
Fudan University

Recruiting

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer (PTCA199-3)

Metastatic Pancreatic Adenocarcinoma

China
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
Fudan University

Recruiting

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer (PTCA199-5)

Chemotherapy-induced Nausea and Vomiting | Pancreatic Cancer Stage IV

China
Georgetown University
AstraZeneca

Recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States
Brandon Huffman
Stand Up To Cancer; Lustgarten Foundation; K-Group, Beta, Inc., a wholly owned...

Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
NYU Langone Health

Recruiting

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Pancreatic Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
West China Hospital

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation (BCIRT-01)

Muscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 Inhibitor

China
Fudan University

Not yet recruiting

Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC

Pancreatic Neoplasms

China
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Daiichi Sankyo, Inc.
AstraZeneca

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Breast Cancer

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

PDAC - Pancreatic Ductal Adenocarcinoma
RemeGen Co., Ltd.

Recruiting

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

NMIBC

China
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Zhang Xiaofeng,MD
College of Pharmaceutical Sciences at Zhejiang University; The Innovation Institute...

Not yet recruiting

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Pancreatic Cancer

China
Guangxi Medical University

Not yet recruiting

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Immune Checkpoint Inhibitors
Sutro Biopharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Korea, Republic of, Israel, Singapore, Canada
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Akeso

Not yet recruiting

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer (OVERPASS)

Pancreatic Cancer

Italy
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
Morten Ladekarl
Odense University Hospital; Aarhus University Hospital; Vejle Hospital; Herlev... and other collaborators

Recruiting

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer

Pancreas Cancer | Non-Resectable Pancreas Carcinoma

Denmark
Brown University
Cures Within Reach; Lifespan; Legorreta Cancer Center at Brown University

Recruiting

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (TASUC-Neo)

Urothelial Carcinoma Bladder | Androgen Receptor Positive

United States
Centre Hospitalier Universitaire, Amiens

Not yet recruiting

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers (NIVOCHIMLOC)

Squamous Cell Carcinoma of the Head and Neck | Paclitaxel | Nivolumab | Carboplatin

France

Search clinical trials for: Gemcitabine Hydrocholoride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations